Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study

BACKGROUND: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease and a leading cause of childhood disability. The objective of this study was to characterize the PK, safety, and taste acceptability of tofacitinib in patients with JIA. METHODS: This Phase 1, open-label,...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pediatr Rheumatol Online J
Hlavní autoři: Ruperto, Nicolino, Brunner, Hermine I., Zuber, Zbigniew, Tzaribachev, Nikolay, Kingsbury, Daniel J., Foeldvari, Ivan, Horneff, Gerd, Smolewska, Elzbieta, Vehe, Richard K., Hazra, Anasuya, Wang, Rong, Mebus, Charles A., Alvey, Christine, Lamba, Manisha, Krishnaswami, Sriram, Stock, Thomas C., Wang, Min, Suehiro, Ricardo, Martini, Alberto, Lovell, Daniel J.
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2017
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5745974/
https://ncbi.nlm.nih.gov/pubmed/29282090
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12969-017-0212-y
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky